<DOC>
	<DOCNO>NCT02756624</DOCNO>
	<brief_summary>This study evaluate safety tolerability AC-170 Ophthalmic Solution</brief_summary>
	<brief_title>A Multi-Center , Vehicle-Controlled , Parallel-Group Study Evaluating Safety AC-170 Ophthalmic Solution</brief_title>
	<detailed_description>Central Cornea Endothelial Cell Counts do subset approximately 150 subject complete 100 subject part safety measure .</detailed_description>
	<mesh_term>Cetirizine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>least 2 year age able selfadminister eye drop parent/legal guardian available purpose le 18 year old history family history atopic disease ( include allergic conjunctivitis ) ocular health within normal limit know contraindication sensitivity study medication component ocular condition , opinion investigator , could affect subject safety trial parameter use disallowed medication period indicate prior enrollment study pregnant , nursing , plan pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>